http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
-
Novavax to Host Conference Call to Discuss Second Quarter Financial Results and Operational Highlights on August 5, 2021
-
Novavax (NVAX) Publishes Results of United Kingdom Phase 3 Clinical Trial in NEJM, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
-
Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of COVID-19 Vaccine
-
Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum
-
Novavax to Participate in National Vaccine Advisory Committee Meeting
-
Novavax (NVAX) Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
-
Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
-
Novavax (NVAX) COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
-
Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
-
Novavax (NVAX) Announces Positive Data from Three Studies of its Vaccine Against South African Strain
-
Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
-
Novavax to Host Maryland Governor Larry Hogan at Site of Future Novavax Vaccines Innovation Campus and Global Headquarters
-
Novavax to Participate in Panel at BIO Digital 2021
-
Novavax to Participate in Jefferies Virtual Healthcare Conference
-
Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update
-
Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea
-
Novavax Honored by Maryland Tech Council During 2021 Industry Awards Celebration
-
Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
-
Novavax (NVAX) Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
-
Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate
-
Novavax (NVAX) and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
-
Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
-
Novavax (NVAX) Announces NEJM Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant
-
New England Journal of Medicine Publishes Phase 2b Clinical Trial Results Demonstrating Efficacy of Novavax COVID-19 Vaccine Against the B.1.351 Variant
-
Novavax (NVAX) Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
-
Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
-
Novavax to Host Conference Call to Discuss First Quarter Financial Results and Operational Highlights on May 10, 2021
-
Novavax (NVAX) Reports Publication of Data from Phase 2b Clinical Trial for Malaria Vaccine Candidate, R21, in Children Demonstrating 77% Efficacy
-
Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet
-
Novavax (NVAX) to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
-
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations
-
Novavax (NVAX) announces Gale E. Smith, Ph.D. promoted to Senior Vice President, Greg Covino to step down as CFO
-
Novavax Announces Leadership Updates
-
Novavax (NVAX) Initiates COVID-19 Vaccine Clinical Trial Crossover
-
Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
-
Novavax CEO Stan Erck to Participate in Longwood Healthcare Leaders Meeting
-
GSK (GSK) to support manufacture of Novavax' (NVAX) COVID-19 vaccine
-
GSK to support manufacture of Novavax' COVID-19 vaccine
-
Novavax (NVAX) COVID-19 Vaccine Shows High Levels of Efficacy Against Original and Variant COVID-19 Strains
-
Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
-
Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat
-
Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
-
Novavax (NVAX), Takeda (TAK) Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
-
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
-
Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan
-
Novavax (NVAX) Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
-
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
-
Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico
-
Novavax (NVAX) Enters MOU with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine

